Which wegovy weight loss drug option suits your goals?
Wegovy Weight Loss Drug vs Mounjaro: Mechanism Comparison
The fundamental difference between Wegovy weight loss drug and Mounjaro lies in their hormonal mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, reducing appetite and promoting satiety after smaller meals. This single-hormone approach has been extensively studied in the STEP trial programme, demonstrating consistent weight management results when used alongside lifestyle modifications.
Mounjaro uses tirzepatide, which targets both GIP and GLP-1 receptors—a dual-hormone approach that may offer different benefits for certain patients. The choice between single and dual-hormone therapy often depends on your medical history, current medications, and how your body responds to treatment. Our prescribers at EverydayMeds assess both options during your clinical consultation, ensuring the wegovy weight loss drug selection aligns with your individual circumstances and weight management goals.
Wegovy Weight Loss Drug Pricing: Complete Cost Breakdown
Understanding the true cost of Wegovy weight loss drug treatment helps you plan your weight management journey effectively. Single pens start at £79.99 for the 0.25mg starter dose (weeks 1-4), progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to the maintenance dose of £209.99 (2.4mg). New customers apply code FIRST40 at checkout, while returning customers use DOSE25 to access these competitive prices through our GPhC-registered pharmacy.
Our bundle options provide convenient multi-month supply without repeated ordering. The Intro Trio (0.25mg, 0.5mg, 1mg) covers your first 12 weeks for £299.99, while the Ultimate Stability Trio provides three months of maintenance 2.4mg doses for £649.99. Compared to Mounjaro's dosing structure, Wegovy weight loss drug follows a more gradual five-dose escalation, potentially offering better tolerability during the initial months of treatment.
Clinical Evidence for Wegovy Weight Loss Drug Efficacy
The STEP clinical trial programme provides robust evidence for Wegovy weight loss drug effectiveness when combined with lifestyle modifications. In STEP 1, patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 5 demonstrated sustained results, with patients maintaining approximately clinically studied weight loss at two years.
The SELECT cardiovascular outcomes trial revealed an additional benefit beyond weight management—a 20% reduction in major cardiovascular events (HR 0.80) in patients with established cardiovascular disease. These results contributed to NICE TA875 recommendations for Wegovy weight loss drug use within specialist weight management programmes, positioning it as an evidence-based treatment option rather than a cosmetic intervention.
How Wegovy Weight Loss Drug Works in Your Body
Wegovy weight loss drug functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a hormone naturally released by your intestines after eating. This prescription-only medicine works primarily in your brain's appetite centres, reducing hunger signals and enhancing feelings of fullness after smaller portions. The once-weekly injection delivered via FlexTouch pen maintains consistent hormone levels, supporting appetite regulation throughout the week. Unlike stimulant-based appetite suppressants, Wegovy's mechanism works with your body's natural satiety pathways, potentially reducing food cravings and emotional eating patterns. The treatment requires concurrent lifestyle modifications—reduced-calorie diet and increased physical activity—to achieve optimal weight management outcomes as demonstrated in clinical trials.
Streamlined Ordering Process for Wegovy Weight Loss Drug
Accessing Wegovy weight loss drug through EverydayMeds involves a straightforward three-step process designed for convenience and safety. Your journey begins with a comprehensive 3-minute online clinical assessment covering medical history, current medications, weight management goals, and contraindications. Our qualified prescribers review your assessment within standard 3 working days (or 24 hours with express service), ensuring Wegovy is clinically appropriate for your circumstances. Once approved, your prescription-only medicine is dispatched via next-day delivery in temperature-controlled packaging, maintaining the cold-chain integrity essential for medication effectiveness. All orders include detailed administration guidance, dose escalation schedules, and access to our clinical support team throughout your treatment journey.
Storage and Practical Considerations for Wegovy Weight Loss Drug
Proper storage of Wegovy weight loss drug ensures medication stability and effectiveness throughout your treatment. Unopened pens must be refrigerated at 2-8°C until first use, after which they can remain at room temperature below 30°C for up to 6 weeks—a significant advantage over Mounjaro's 21-day room temperature limit. This storage flexibility makes Wegovy more practical for travel, work schedules, and lifestyle demands. The FlexTouch pen design requires minimal preparation, with dose escalation following a mandatory schedule: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance from week 17 onwards. Each pen contains four doses, delivered subcutaneously once weekly, preferably on the same day each week for optimal hormone level consistency.
Wegovy Weight Loss Drug vs Mounjaro: Treatment Duration and Sustainability
Long-term commitment distinguishes successful wegovy weight loss drug treatment from short-term interventions, with both Wegovy and Mounjaro designed for ongoing weight management rather than quick fixes. STEP 1 extension data shows patients regained approximately two-thirds of lost weight within one year of stopping treatment, emphasising that weight management requires sustained medical support. This pattern applies to both medications, making the choice between Wegovy and Mounjaro a decision about long-term lifestyle compatibility rather than speed of results.
Wegovy weight loss drug offers a five-dose escalation compared to Mounjaro's six-dose progression, potentially providing a gentler introduction for patients concerned about gastrointestinal side effects. The maintenance phase with 2.4mg weekly injections may continue indefinitely under medical supervision, with regular reviews ensuring continued clinical benefit. Our EverydayMeds clinical team supports both treatment pathways, helping patients understand that successful weight management combines medical intervention with sustainable lifestyle modifications regardless of which prescription-only medicine they choose.
Making Your Wegovy Weight Loss Drug Decision with Expert Support
Choosing between Wegovy weight loss drug and Mounjaro requires personalised clinical assessment rather than generic treatment selection, which is why EverydayMeds offers both options through our qualified prescriber network. Your medical history, current medications, lifestyle factors, and weight management goals all influence which GLP-1 based treatment may be most suitable. New customers can start their assessment today using code FIRST40 for competitive pricing, while our clinical team provides ongoing support throughout your treatment journey. Whether you select Wegovy's proven semaglutide mechanism or Mounjaro's dual-hormone approach, our GPhC-registered pharmacy (#9012878) ensures safe, legal access to these prescription-only medicines with professional oversight. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and discuss which wegovy weight loss drug option aligns with your personal weight management strategy.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
